Discover BAM15 CAS: 210302-17-3 : The Revolutionary Compound for Fat Burning and Metabolic Health

BAM15 is a novel, small-molecule mitochondrial uncoupler that selectively disrupts the proton gradient across the inner mitochondrial membrane, leading to increased energy expenditure without adenosine triphosphate (ATP) production. Unlike traditional uncouplers (e.g., 2,4-dinitrophenol, DNP), BAM15 demonstrates a high therapeutic index and tissue specificity, minimizing systemic toxicity. It promotes "mild uncoupling," which accelerates fatty acid oxidation and reduces reactive oxygen species (ROS) accumulation, offering a dual mechanism for metabolic regulation. Preclinical studies highlight its ability to enhance thermogenesis in adipose tissue while avoiding excessive hyperthermia or lactic acidosis. 

1. Enhanced Metabolism: BAM15 acts as a metabolic enhancer, promoting efficient energy production within cells by increasing mitochondrial uncoupling.

2. Supports Weight Management: By stimulating metabolic pathways, BAM15 may help support healthy weight management goals and promote fat loss.

3. Boosts Energy Levels: Users of BAM15 often report increased energy levels and improved endurance during physical activity, making it a popular choice among       athletes and fitness enthusiasts.

4. Potential Health Benefits: Beyond its effects on metabolism, BAM15 has shown promise in preclinical studies for its potential to improve insulin sensitivity, reduce inflammation, and enhance overall metabolic health.

Usage

BAM15 is primarily investigated for research and therapeutic purposes in metabolic disorders. Key usage includes:

1.Dosage Forms:

Oral administration (e.g., formulated in carboxymethylcellulose suspensions).

In vitro models: dissolved in DMSO for cell-based assays (typical concentrations: 1–10 μM).

2.Therapeutic Targets:

Obesity: Reduces adiposity by increasing basal metabolic rate.

Non-alcoholic fatty liver disease (NAFLD): Lowers hepatic lipid accumulation.

Type 2 Diabetes: Improves insulin sensitivity via AMPK activation.

3.Preclinical Models:

Effective in diet-induced obese (DIO) mice and genetically obese (ob/ob) models.

Administered at 10–50 mg/kg/day, showing dose-dependent weight loss without cardiac toxicity.